01. Product portfolioProTransStudy TeamCellaviva
02. About NextCellBusiness ConceptVision, mission, strategyHistory
OrganisationCompany Structure
03. InvestorsRights Issue 2024NextCell as an investmentFinancial CalendarFinancial ReportsCorporate GovernanceCertified AdviserThe ShareArchive
04. NewsQ&A with CEOPress ReleasesEventsCompany Presentations
05. ContactContact InformationSubscribe
English
/
Svenska

CSO Lindsay Davies Co-Chairs ISCT Europe 2024 Meeting

September 3, 2024

NextCell Pharma AB ("NextCell" or the "Company", Nasdaq First North Growth Market: NXTCL), a leader in advanced cell therapy and immunotherapy research, is proud to announce that Dr. Lindsay Davies, the company’s Chief Scientific Officer (CSO) and ISCT Europe Regional Secretary, serves as Co-Chair together with Dr. Massimiliano Gnecchi of the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting, held in Gothenburg, Sweden, from September 4-6.

"We are thrilled to have Dr. Davies representing NextCell Pharma at such an influential event," says Mathias Svahn, CEO of NextCell Pharma AB. "Her expertise in cell therapy and her leadership within ISCT underscore our company's commitment to advancing the science and therapeutic potential of cell-based treatments. This meeting is a great opportunity to showcase the progress NextCell is making in the field of advanced therapies, in particular the 5-year efficacy data with a single infusion of ProTrans for treatment of type-1 diabetes."

The ISCT Europe 2024 Regional Meeting brings together leading researchers, clinicians, and industry professionals from around the world to discuss the latest advances and challenges in the field of cell and gene therapy. This prestigious event focuses on cutting-edge scientific breakthroughs, regulatory trends, and innovative approaches to translating research into clinical applications, aiming to accelerate the development of new therapies for patients.

Dr. Lindsay Davies, in her dual role as CSO of NextCell Pharma AB and ISCT Europe Regional Secretary, has played a pivotal role in organizing the event and will be involved heavily with and steering the discussions during the event. Her leadership has been instrumental in shaping the program, which features high-profile speakers and interactive sessions addressing the most pressing issues in the rapidly evolving field of regenerative medicine.

The ISCT Europe 2024 Regional Meeting covers a wide range of topics, including innovations in stem cell therapies, gene editing technologies, regulatory hurdles, and strategies for commercialization. The event provides a platform for collaboration among industry leaders, academic institutions, and regulatory bodies to further the development of next-generation therapies aimed at treating chronic diseases and those indications with unmet medical needs.

NextCell Pharma AB continues to be at the forefront of cell therapy development with its lead product candidate ProTrans, a mesenchymal stromal cell-based therapy designed to treat autoimmune diseases such as type 1 diabetes. The company remains dedicated to pushing the boundaries of regenerative medicine through scientific innovation, clinical research, and partnerships with leading organizations in the biotech sector.

About ISCT

The International Society for Cell and Gene Therapy (ISCT) is a global association with a focus on driving the translation of scientific research into clinical applications of cell and gene therapies. With over 1,700 members in 50+ countries, ISCT connects academic, regulatory, and commercial stakeholders to advance the field of regenerative medicine.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB

NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.

Download attachmentRead full press release on Cision (external link)
2021-04-27
Presentation of the pediatric diabetes study tomorrow Wednesday
NextCell Pharma AB (“NextCell”) has invited Professor Per-Ola Carlsson to present study design and rational for the pediatric study, ProTrans-Young. The trial, recently approved, is a phase I / II study with a total of 66 patients with newly diagnosed type-1 diabetes. The presentation will be broadcasted tomorrow, Wednesday April 28, at 14:00. Afterwards, there is an opportunity to ask questions to Professor Carlsson and NextCell's CEO and CSO. https://youtu.be/kE4POLMlXWA.
NextCell Pharma AB (“NextCell”) has invited Professor Per-Ola Carlsson to present study design and rational for the pediatric study, ProTrans-Young. The trial, recently approved, is a phase I / II study with a total of 66 patients with newly diagnosed type-1 diabetes. The presentation will be br...
Read moreRead more
2021-04-14
Pediatric diabetes study with stem cells approved
NextCell Pharma AB ("NextCell") announces today that Uppsala University Hospital and the principal investigator, Professor Per-Ola Carlsson, have been granted approval from the Medical Products Agency and the Swedish Ethical Review Authority to conduct a clinical drug trial with ProTrans™ to treat children and adolescents with type-1 diabetes. The study is a phase I / II study with a total of 66 patients. The first six patients treated will be evaluated for safety. The first six patients, three adolescents (12-18 years) and three children (7-11 years), will be treated and assessed for safety.
NextCell Pharma AB ("NextCell") announces today that Uppsala University Hospital and the principal investigator, Professor Per-Ola Carlsson, have been granted approval from the Medical Products Agency and the Swedish Ethical Review Authority to conduct a clinical drug trial with ProTrans™ to trea...
Read moreRead more
2021-03-31
NextCell welcomes Consensus Sverige Selectas as a shareholder
The Board of Directors of NextCell Pharma AB (”NextCell or the ”Company”) has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on a directed issue of 666,666 new shares (the “Share Issue”) to Consensus Sverige Select (”Consensus”). The subscription price in the share issue amounts to SEK 15 per new share and the Company receives approximately SEK 10 million in issue proceeds. The Board of Directors of NextCell has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on the Share
The Board of Directors of NextCell Pharma AB (”NextCell or the ”Company”) has today, based on the authorization granted by the Annual General Meeting held on 24 November 2020, resolved on a directed issue of 666,666 new shares (the “Share Issue”) to Consensus Sverige Select (”Consensus”). The sub...
Read moreRead more
2021-03-02
The stem cell company NextCell invests in own production facility
The stem cell company NextCell Pharma AB (“NextCell” or “the Company”) announces today that they have entered into an agreement with the property manager Hemsö and the clean room supplier QleanAir, to build a full-scale production facility. This new production facility will be directly connected to the Company's existing office and clean room in the Novum building, next to Karolinska University Hospital in Huddinge. The construction will take place later this spring and the premises are expected to be completed during the third quarter of 2021. The significant upcomming medical need for
The stem cell company NextCell Pharma AB (“NextCell” or “the Company”) announces today that they have entered into an agreement with the property manager Hemsö and the clean room supplier QleanAir, to build a full-scale production facility. This new production facility will be directly connected ...
Read moreRead more
2021-02-02
Canadian Trial for ProTrans in COVID-19
NextCell Pharma AB (“NextCell”) today announces that Health Canada and the McGill University Health Centre Research Ethics Board have authorized the clinical trial entitled “Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Mesenchymal Stromal Cells (ProTrans™): a Randomized Phase II Controlled Clinical Trial”. The sponsor for this trial is the Research Institute of the McGill University Health Centre. The trial will enrol 48 patients with severe pneumonia associated with confirmed COVID-19 (SARS-CoV-2) infection,
NextCell Pharma AB (“NextCell”) today announces that Health Canada and the McGill University Health Centre Research Ethics Board have authorized the clinical trial entitled “Treatment of Respiratory Complications Associated with COVID-19 Infection Using Wharton’s Jelly (WJ)-Umbilical Cord (UC) Me...
Read moreRead more
2021-01-29
NextCell Pharma publishes Interim Report 1 2020/2021
NextCell Pharma AB (publ) (NXTCL) publishes its Interim Report 1 for the period September 1, 2020 - November 30, 2020 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. First quarter (2020-09-01 until 2020-11-30) · Operating income amounted to SEK 1 148 187 (1 222 087) · Operating result amounted to SEK -17 680 697 (-17 997 787).. · Earnings per share
NextCell Pharma AB (publ) (NXTCL) publishes its Interim Report 1 for the period September 1, 2020 - November 30, 2020 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report NextCells share is traded on Nasdaq First North Growth Market under...
Read moreRead more
2020-12-23
NextCell Pharma’s rights issue was oversubscribed
NextCell Pharma AB ("NextCell" or the ”Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders of approximately SEK 150 million (the “Rights Issue”). The Rights Issue was oversubscribed. Thus, no guarantees have been utilized. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR
NextCell Pharma AB ("NextCell" or the ”Company”) announces today the outcome in the Company’s new issue of shares with preferential rights for existing shareholders of approximately SEK 150 million (the “Rights Issue”). The Rights Issue was oversubscribed. Thus, no guarantees have been utilized. ...
Read moreRead more
2020-12-16
NextCell Pharma publishes prospectus supplement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a supplement to the prospectus regarding the invitation to subscribe for shares in the Company’s resolved rights issue, which was approved by the Swedish
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SWITZERLAND, SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFU...
Read moreRead more
This website uses cookies in order to improve the user experience. Read more
Preferences
DenyAccept